Page last updated: 2024-11-05

ticlopidine and Atrial Fibrillation

ticlopidine has been researched along with Atrial Fibrillation in 204 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk."9.24Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017)
"Dabigatran as compared to phenprocoumon has no impact on ADP-induced platelet aggregation in atrial fibrillation patients neither with nor without concomitant clopidogrel therapy."9.20Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). ( Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D, 2015)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."9.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."9.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."9.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"Aspirin offers modest reduction in stroke in patients with atrial fibrillation."9.13Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."9.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)."9.11Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004)
"This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin."9.10A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."8.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin."8.87Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011)
"A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban."7.83Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."7.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."7.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation."7.81Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. ( Hwang, JC; Jun, JH, 2015)
" We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)."7.79Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."7.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable."7.78Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."7.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."7.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
"To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk."5.24Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017)
"Dabigatran as compared to phenprocoumon has no impact on ADP-induced platelet aggregation in atrial fibrillation patients neither with nor without concomitant clopidogrel therapy."5.20Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). ( Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D, 2015)
"This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events."5.20Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015)
"Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction."5.20Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015)
"The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation."5.17Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013)
"We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score."5.17The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."5.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
" In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5."5.14Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010)
"We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation."5.14Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. ( Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S, 2010)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."5.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"Aspirin offers modest reduction in stroke in patients with atrial fibrillation."5.13Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008)
"In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 countries."5.13Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. ( Commerford, P; Connolly, SJ; Eikelboom, J; Flaker, G; Franzosi, MG; Healey, JS; Pogue, J; Yusuf, S, 2008)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."5.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients."5.12Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. ( Connolly, SJ; Healey, JS; Hohnloser, SH; Pajitnev, D; Pfeffer, MA; Pogue, J; Yusuf, S, 2007)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."5.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)."5.11Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004)
"This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin."5.10A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002)
"Clopidogrel combined with aspirin is routinely prescribed after coronary artery stenting, in patients with acute coronary syndromes, and recently to prevent stroke in patients with acute minor ischemic stroke and TIA."4.91Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. ( Bakheet, MF; Hart, RG; Pearce, LA, 2015)
" Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor."4.90Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? ( Alpert, JS; Asencio, LA; Huang, JJ, 2014)
" In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis."4.90Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014)
"The role of aspirin in the early management of stroke is well established."4.89Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."4.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin."4.87Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011)
"The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes."4.87Triple therapy in hospitalized patients: facts and controversies. ( Smetana, GW; Srour, JF, 2011)
" The ACTIVE-W study was a noninferiority comparison of the combination of clopidogrel and acetylsalicylic acid versus oral anticoagulant among patients with atrial fibrillation."4.84Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. ( Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG, 2008)
"Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation."4.84Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007)
" Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%."4.82[Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005)
"Warfarin therapy achieving an International Normalized Ratio between 2 and 3 has been shown to be effective in preventing stroke."4.82New possibilities in anticoagulant management of atrial fibrillation. ( Waldo, AL, 2004)
"Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity."4.82Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003)
"English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders."4.79Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994)
" Due to previous atrial fibrillation and ischaemic heart disease, this patient was treated with both dabigatran and clopidogrel."3.88Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. ( Fredgart, M; Gill, S, 2018)
"Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])."3.83Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016)
"A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban."3.83Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."3.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."3.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"Secondary prevention treatment with aspirin/ clopidogrel, beta blockers, inhibitors of the rennin-angiotensin-aldosterone converting system and statins reduces the morbidity and mortality of patients after acute coronary syndrome (ACS)."3.81[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. ( Elis, A; Lishner, M; Pereg, D; Yahia, DH, 2015)
"Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation."3.81Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. ( Hwang, JC; Jun, JH, 2015)
"To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention."3.80Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. ( He, B; Kun, L; Liu, X; Wu, B, 2014)
" However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding."3.80Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014)
"Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions."3.79The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. ( Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."3.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
" We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)."3.79Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013)
"Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge."3.78Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012)
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years."3.78[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012)
" Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel."3.78Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable."3.78Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012)
"Practice guidelines recommend anticoagulation therapy with warfarin for stroke prevention in patients with atrial fibrillation (AF)."3.78Warfarin use in nursing home residents: results from the 2004 national nursing home survey. ( Ghaswalla, PK; Harpe, SE; Slattum, PW, 2012)
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel."3.78Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012)
"Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA)."3.77Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. ( Bushnell, CD; Lopes, RD; Olson, DM; Pan, W; Peterson, ED; Shah, BR; Zhao, X, 2011)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."3.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."3.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
"Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole."3.71Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001)
"Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke."3.70Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000)
"(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death."3.70Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000)
"Thirty patients (18 women, 12 men) with permanent or paroxysmal atrial fibrillation were treated with a new antiplatelet drug, ticlopidine, in order to study platelet aggregation behaviour, to see whether the drug prevents thromboembolisms and to observe side-effects over a period of 6 months."3.67Platelet aggregation behaviour in patients treated with ticlopidine. ( Balbarini, A; Evangelisti, L; Gherarducci, G; Giordani, R; Mariani, M; Petronio, AS; Preti, R, 1987)
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."2.48Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies."2.43Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005)
"Stroke is the most feared complication of atrial fibrillation, and the risk of stroke increases markedly with age."2.42Trials of newer approaches to anticoagulation in atrial fibrillation. ( Cooper, HA, 2004)
"Six years later after a left cerebral transient ischemic attack aspirin was replaced by ticlopidine."2.41[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine]. ( Auer, J; Berent, R; Haidenthaler, A; Hinterholzer, G; Höbling, W; Knoflach, P, 2000)
"Removal of the thrombus and maze procedure were performed at the same time."2.40[A case of mobile left atrial thrombus without mitral valve disease]. ( Asada, K; Hasegawa, Y; Kodama, T; Kondou, K; Matsuyama, N; Minohara, S; Okamoto, J; Okamoto, K; Sasaki, S; Sawada, Y, 1997)
"Bleeding was the primary outcome."1.46Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017)
"Device-related thrombus remains a major concern because it may result in recurrent embolic events."1.46WATCHMAN device-related thrombus successfully treated with apixaban: A case report. ( Chan, PH; Kwok, OH; Lam, CC; Lam, YY; Siu, CW; Wong, CK, 2017)
"Aspirin (53."1.43Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016)
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction."1.40Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014)
" Primary end point was the combined incidence of major adverse coronary events and major bleedings."1.36Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. ( Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)
"Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition."1.33Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006)
"Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1."1.32[Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003)
"The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention."1.32Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003)
"Among 801 patients not receiving treatment for thromboembolism, the annual rate was 0."1.30[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. ( , 1998)

Research

Studies (204)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.49)18.7374
1990's9 (4.41)18.2507
2000's70 (34.31)29.6817
2010's123 (60.29)24.3611
2020's1 (0.49)2.80

Authors

AuthorsStudies
Baturina, O1
Andreev, D1
Fedina, L1
Mirzaev, K1
Ivashchenko, D1
Ryzhikova, K1
Grishina, E1
Bochkov, P1
Shevchenko, R1
Sychev, D1
Melkonian, M1
Jarzebowski, W1
Pautas, E1
Siguret, V1
Belmin, J1
Lafuente-Lafuente, C1
Pareek, M1
Bhatt, DL6
Ten Berg, JM4
Kristensen, SD1
Grove, EL1
Choi, HI1
Ahn, JM1
Kang, SH1
Lee, PH1
Kang, SJ1
Lee, SW1
Kim, YH1
Lee, CW1
Park, SW1
Park, DW1
Park, SJ1
Park, SM1
Jeong, H1
Jung, MH1
Hong, KS1
Hong, MK1
Bang, CS1
Kim, CY1
Yuan, C1
Zhong, L1
Huang, RC1
Cannon, CP2
Oldgren, J1
Lip, GYH4
Ellis, SG2
Kimura, T1
Maeng, M1
Merkely, B1
Zeymer, U2
Gropper, S1
Nordaby, M1
Kleine, E1
Harper, R1
Manassie, J1
Januzzi, JL1
Steg, PG1
Hohnloser, SH6
Wong, CK1
Chan, PH1
Lam, CC1
Kwok, OH1
Lam, YY1
Siu, CW1
Duerschmied, D1
Brachmann, J1
Darius, H1
Frey, N1
Katus, HA1
Rottbauer, W1
Schäfer, A1
Thiele, H1
Bode, C2
Fredgart, M1
Gill, S1
Nietlispach, F1
Gloekler, S1
Krause, R1
Shakir, S1
Schmid, M1
Khattab, AA1
Wenaweser, P1
Windecker, S1
Meier, B1
Stiefelhagen, P3
Tanrıkulu, A1
Ağırbaşlı, M1
Lamberts, M5
Gislason, GH4
Olesen, JB3
Kristensen, SL2
Schjerning Olsen, AM1
Mikkelsen, A1
Christensen, CB1
Lip, GY16
Køber, L4
Torp-Pedersen, C4
Hansen, ML6
Apostolakis, S2
Shantsila, E2
Seivani, Y1
Abdel-Wahab, M1
Geist, V1
Richardt, G1
Sulimov, DS1
El-Mawardy, M1
Toelg, R1
Akin, I1
Steinberg, BA1
Kim, S1
Piccini, JP6
Fonarow, GC3
Lopes, RD7
Thomas, L3
Ezekowitz, MD1
Ansell, J2
Kowey, P2
Singer, DE4
Gersh, B1
Mahaffey, KW4
Hylek, E1
Go, AS4
Chang, P2
Peterson, ED6
McCormack, T1
Suh, SY1
Kang, WC1
Oh, PC1
Choi, H1
Moon, CI1
Lee, K1
Han, SH1
Ahn, T1
Choi, IS1
Shin, EK1
Wu, B1
Kun, L1
Liu, X1
He, B1
Stevens, SR1
White, HD2
Nessel, CC1
Goodman, SG1
Patel, MR1
Becker, RC1
Halperin, JL5
Hacke, W4
Hankey, GJ4
Califf, RM1
Fox, KA6
Breithardt, G1
Enomoto, Y1
Iijima, R1
Tokue, M1
Ito, N1
Nagashima, Y1
Araki, T1
Yamazaki, K1
Utsunomiya, M1
Hori, M1
Itaya, H1
Shiba, M1
Hara, H1
Nakamura, M1
Sugi, K1
Lassen, JF1
Mikkelsen, AP1
Sørensen, R2
Rubboli, A4
Schlitt, A4
Kiviniemi, T2
Biancari, F2
Karjalainen, PP1
Valencia, J1
Laine, M1
Kirchhof, P2
Niemelä, M2
Vikman, S2
Airaksinen, KE3
Ice, DS1
Shapiro, TA1
Gnall, EM1
Kowey, PR1
Asencio, LA1
Huang, JJ1
Alpert, JS1
Lee, J1
Burke, DT1
Llull, L1
Martín, V1
Vidal, B1
Cervera, A1
Thompson, PL2
Verheugt, FW7
Dewilde, WJ2
Janssen, PW2
Storey, RF2
Adriaenssens, T2
Verma, A1
Cairns, JA2
Mitchell, LB1
Macle, L1
Stiell, IG1
Gladstone, D1
McMurtry, MS1
Connolly, S3
Cox, JL1
Dorian, P2
Ivers, N1
Leblanc, K1
Nattel, S1
Healey, JS6
Thompson, AG1
Judkins, C1
Braun, OÖ1
Bico, B1
Chaudhry, U1
Wagner, H1
Koul, S1
Tydén, P1
Scherstén, F1
Jovinge, S1
Svensson, PJ1
Gustav Smith, J1
van der Pals, J1
Bakheet, MF1
Pearce, LA2
Hart, RG11
Lu, W1
Chen, L1
Wang, Y1
Yao, Y1
Fu, C1
Zuo, P1
Ma, G1
Dzeshka, MS1
Brown, RA1
Sandhu, RK1
Pfeffer, MA3
Yuan, F1
Yusuf, S12
Connolly, SJ12
McAlister, FA1
Capodanno, D1
Horie, N1
Kaminogo, M1
Izumo, T1
Hayashi, K1
Tsujino, A1
Nagata, I1
Angoulvant, D1
Villejoubert, O1
Bejan-Angoulvant, T1
Ivanes, F1
Saint Etienne, C1
Fauchier, L1
Gibson, CM1
Mehran, R1
Halperin, J1
Verheugt, F1
Wildgoose, P1
van Eickels, M1
Cohen, M1
Husted, S1
Peterson, E1
Fox, K1
Vavuranakis, M1
Kalogeras, K1
Vrachatis, D1
Kariori, M1
Moldovan, C1
Mpei, E1
Lavda, M1
Kolokathis, AM1
Siasos, G1
Tousoulis, D1
Gao, F2
Shen, H2
Wang, ZJ2
Yang, SW2
Liu, XL2
Zhou, YJ2
Blann, AD2
Skjøth, F1
Rasmussen, LH1
Larsen, TB1
Agewall, S1
Huber, K2
Jun, JH1
Hwang, JC1
Yahia, DH1
Pereg, D1
Lishner, M1
Elis, A1
Martischnig, AM1
Mehilli, J1
Pollak, J1
Petzold, T1
Fiedler, AK1
Mayer, K1
Schulz-Schüpke, S1
Sibbing, D1
Massberg, S1
Kastrati, A1
Sarafoff, N1
Di Pasquale, G1
Fabiaña, N1
Ramaswami, AP1
Ang, ES1
De Silva, DA1
Pankert, M1
Salaun, E1
Cuisset, T1
Bonnet, JL1
Ketterer, U1
D'Ancona, G1
Siegel, I1
Ortak, J1
Ince, H1
Kische, S1
Rao, M1
Simon, DN1
Gersh, BJ1
Hylek, EM2
Sambola, A1
Mutuberría, M1
García Del Blanco, B1
Alonso, A1
Barrabés, JA1
Bueno, H1
Alfonso, F1
Cequier, A1
Zueco, J1
Rodríguez-Leor, O1
Tornos, P1
García-Dorado, D1
Reddy, VY2
Akehurst, RL1
Armstrong, SO1
Amorosi, SL1
Brereton, N1
Hertz, DS1
Holmes, DR1
Zhang, N1
Chen, KY1
Zhao, J1
Xu, G1
Li, G1
Liu, T1
Faza, NN1
Mentias, A1
Parashar, A1
Chaudhury, P1
Barakat, AF1
Agarwal, S2
Wayangankar, S1
Murat Tuzcu, E1
Kapadia, SR1
Hoshi, T1
Sato, A1
Nogami, A1
Gosho, M1
Aonuma, K1
Jackson, LR1
Cyr, DD1
Roe, MT2
Neely, ML1
Martinez, F1
Lüscher, TF2
Winters, KJ1
Armstrong, PW1
Prabhakaran, D1
Magnus Ohman, E1
Corbalán, R1
Dugo, D1
Bordignon, S1
Konstantinou, A1
Perrotta, L1
Fürnkranz, A1
Chun, JK1
Schmidt, B1
Fahed, E1
Ghauche, J1
Rahme, R1
Okais, N1
Samaha, E1
Nohra, G1
Rizk, T1
Maarrawi, J1
Menassa-Moussa, L1
Moussa, R1
Collet, JP1
Guedeney, P1
Montalescot, G1
Buck, J1
Kaboli, P1
Gage, BF1
Cram, P1
Vaughan Sarrazin, MS1
Wändell, P1
Carlsson, AC1
Holzmann, M1
Ärnlöv, J1
Johansson, SE1
Sundquist, J1
Sundquist, K1
Jolly, SS1
Natarajan, MK1
Jalal, Z1
Dinet, ML1
Combes, N1
Pillois, X1
Renou, P1
Sibon, I1
Iriart, X1
Thambo, JB1
Reiner, MF1
Breitenstein, A1
Holy, EW1
Glanzmann, M1
Amstalden, H1
Stämpfli, SF1
Bonetti, NR1
Falk, V1
Keller, S1
Savarese, G1
Benussi, S1
Maisano, F1
Beer, JH1
Steffel, J1
Camici, GG1
Buerke, M2
Eeckhout, E1
Freedman, SB1
Gershlick, AH1
Tse, HF1
Manzano-Fernández, S1
Pastor, FJ1
Marín, F1
Cambronero, F1
Caro, C1
Pascual-Figal, DA1
Garrido, IP1
Pinar, E1
Valdés, M1
Maegdefessel, L2
Faerber, J1
Bond, SP1
Messow, CM1
Raaz, U1
Werdan, K1
Muenzel, T1
Weiss, C1
Pogue, J8
Eikelboom, J1
Flaker, G4
Commerford, P1
Franzosi, MG2
Pfeffer, M4
Chrolavicius, S4
Boysen, G1
Preobrazhenskiĭ, DV2
Hoppe, UC2
Einecke, D1
Pisters, R2
Dinh, T1
Crijns, HJ2
Chua, D1
Legal, M1
Shalansky, SJ1
Lee, YE1
DeZee, KJ1
Goldstein, LB1
Richard, T1
Butaffuoco, F1
Vanhaeverbeek, M1
Shalimar, S1
Pangtey, GS1
Singh, KK1
Depta, JP1
Zhao, X2
Peacock, WF1
Seet, RC1
Chen, CP1
Lane, DA2
Lee, TH1
Wandeler-Meyer, K1
Bremerich, J1
Christ, M1
Pasceri, V1
Patti, G1
Pristipino, C1
Pelliccia, F1
Irini, D1
Varveri, A1
Roncella, A1
Di Sciascio, G1
Speciale, G1
Laufs, U1
Rosenkranz, S1
Böhm, M1
Diener, HC1
Endres, M1
Grond, M1
Meinertz, T2
Ringelstein, EB1
Röther, J1
Dichgans, M1
Nie, B1
Yan, ZX1
Jia, de A1
Yu, M1
Azuma, J1
Tsao, PS1
Paikin, JS1
Mehta, SR3
Eikelboom, JW5
Samama, MM1
Horellou, MH1
Achkar, A1
Conard, J1
De Caterina, R7
Budaj, A2
Morais, J2
Renda, G3
Clausen, MT1
Fog-Petersen, ML1
Raunsø, J1
Gadsbøll, N1
Folke, F1
Andersen, SS1
Schramm, TK1
Abildstrøm, SZ1
Poulsen, HE1
Paré, G2
Anand, SS2
Hirsh, J3
Simonsen, K1
Geisler, T1
Bigalke, B1
Schwab, M1
Srour, JF1
Smetana, GW1
Khan, M2
Kamal, AK2
Ziegelstein, RC1
Green, A1
Sauder, M1
Garg, N1
Rajpurohit, N1
Clem, JR1
Chaturvedi, S1
Bhattacharya, P1
Shah, BR1
Olson, DM1
Pan, W1
Bushnell, CD1
Cardona, L1
Ana, G1
Luísa, B1
Leal, A1
António, F1
Lídia, S1
Cruz, FR1
Rodríguez-Yáñez, M1
Arias-Rivas, S1
Fernández-Ferro, J1
Leira, R1
Castillo, J1
Blanco, M1
Messinger-Rapport, BJ1
Morley, JE1
Thomas, DR1
Gammack, JK1
Ng, J1
Hohnloser, S4
Fang, MC2
Almadi, MA1
Barkun, A1
Brophy, J1
Mrdovic, I1
Savic, L1
Krljanac, G1
Perunicic, J1
Asanin, M1
Lasica, R1
Antonijevic, N1
Kocev, N1
Marinkovic, J1
Vasiljevic, Z1
Ostojic, M1
Coleman, CI1
Straznitskas, AD1
Sobieraj, DM1
Kluger, J1
Anglade, MW1
Ghaswalla, PK1
Harpe, SE1
Slattum, PW1
Belousov, IuB1
Mareev, VIu1
Iavelov, IS1
Belousov, DIu1
Afanas'eva, EV1
You, JJ1
Howard, PA1
Eckman, MH1
Schulman, S1
Hughes, M1
Spencer, FA1
Manning, WJ1
Ross, S1
Hachamovitch, R1
Menon, V1
Karjalainen, P1
Pietilä, M1
Ylitalo, A1
Puurunen, M1
Lewis, JP1
Shuldiner, AR1
Fosbol, EL1
Wang, TY2
Li, S1
Shah, B1
Mills, RM1
Klaskala, W1
Alexander, KP3
Varughese, CJ1
Petrie, C1
Li, L1
Granger, CB2
Foody, JM1
Funk, M1
Shevelev, VI2
Kanorskiĭ, SG1
Ruwald, MH1
Hansen, CM1
Karasoy, D1
Vavalle, JP1
Rao, SV1
Ten Cate, H1
Coppens, M1
Shestakovska, O1
Hess, CN1
Broderick, S1
Newby, LK1
Shaw, LK1
Alexander, JH1
Kozan, Ö1
Kanorsky, SG1
Azoulay, L1
Dell'Aniello, S1
Simon, T1
Renoux, C1
Suissa, S1
Doshi, SK1
Sievert, H1
Buchbinder, M1
Neuzil, P1
Holmes, D1
Kamath, S1
Chin, BS1
Ono, A1
Fujita, T1
Abe, Y1
Asakura, T1
Sakamoto, N1
Ishikawa, S1
Muroi, S1
Saitoh, F1
Satoh, M1
Suzuki, S1
Ono, M1
Sakabe, A1
Iwai, M1
Sando, M1
Gotou, J1
Watanabe, Y1
Nagata, K1
Maehara, K1
Maruyama, Y1
Meyer, BJ1
Watters, K1
McConn Walsh, R1
Lidell, C1
Svedberg, LE1
Lindell, P1
Bandh, S1
Job, B1
Wallentin, L1
Jessup, DB1
Coletti, AT1
Muhlestein, JB1
Barry, WH1
Shean, FC1
Whisenant, BK1
Cooper, HA1
Di Micco, B1
Di Micco, G1
Niglio, A1
Romano, M1
Di Micco, P1
Tan, KT1
Lorenzoni, R1
Lazzerini, G1
Cocci, F1
Waldo, AL1
Jackson, SL1
Peterson, GM1
Bereznicki, LR1
Tonarelli, SB1
Veloso, HH1
de Paola, AA1
Ederhy, S1
Meuleman, C1
Hammoudi, N1
Janower, S1
Boccara, F1
Cohen, A1
Szapáry, L1
Steinbeck, G1
Hart, R2
Camm, J1
Commerford, PJ1
Flather, M1
Joyner, C1
Anand, I1
Arthur, H1
Avezum, A1
Bethala-Sithya, M1
Blumenthal, M1
Ceremuzynski, L1
Diaz, R1
Frangin, G1
Gaudin, C1
Golitsyn, S1
Goldhaber, S1
Granger, C1
Halon, D1
Hermosillo, A1
Hunt, D1
Jansky, P1
Karatzas, N1
Keltai, M1
Lanas, F1
Lau, CP1
Le Heuzey, JY1
Lewis, BS1
Morillo, C1
Oto, A1
Paolasso, E1
Peters, RJ1
Pfisterer, M1
Piegas, L1
Pipillis, T1
Proste, C1
Sitkei, E1
Swedberg, K1
Synhorst, D1
Talajic, M1
Trégou, V1
Valentin, V1
van Mieghem, W1
Weintraub, W1
Varigos, J1
Sekiya, H1
Noguchi, K1
Ohashi, Y1
Kariya, Y1
Hoshino, Y1
Konishi, H1
Helft, G1
Gilard, M1
Le Feuvre, C1
Zaman, AG1
Karpha, M1
Cheng, Hy1
DeEugenio, D1
Kolman, L1
DeCaro, M2
Andrel, J1
Chervoneva, I1
Duong, P1
Lam, L1
McGowan, C1
Lee, G1
Ruggiero, N1
Singhal, S1
Greenspon, A1
Zimarino, M1
Cid, AR1
Zorio, E1
Haya, S1
Zúñiga, P1
Rueda, J1
Casaña, P1
Cabrera, N1
Arnau, MA1
Aznar, JA1
Pajitnev, D1
Wittes, J1
Wyse, DG1
Gent, M1
Marler, J1
Pritchett, EL1
Berger, PB1
Hu, T1
Topol, EJ1
Matchar, DB1
McCrory, DC1
Barnett, HJ1
Feussner, JR1
Solomon, DH1
Dewarrat, A1
Bogousslavsky, J1
Matsuyama, N1
Asada, K1
Kondou, K1
Kodama, T1
Minohara, S1
Hasegawa, Y1
Sawada, Y1
Okamoto, J1
Okamoto, K1
Sasaki, S1
Ferguson, JJ1
Gonzalez, ER1
Kannel, WB1
Olin, JW1
Raps, EC1
Dyken, ML1
Benavente, O1
Holroyd-Leduc, JM1
Kapral, MK1
Austin, PC1
Tu, JV1
Berent, R1
Hinterholzer, G1
Höbling, W1
Auer, J1
Haidenthaler, A1
Knoflach, P1
Lalouschek, W1
Lang, W1
Müllner, M1
Uchiyama, S1
Yamazaki, M1
Iwata, M1
Petronio, AS1
Evangelisti, L1
Preti, R1
Gherarducci, G1
Balbarini, A1
Giordani, R1
Mariani, M1

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk[NCT02960126]Phase 31,500 participants (Anticipated)Interventional2016-11-30Not yet recruiting
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864]Phase 32,725 participants (Actual)Interventional2014-07-22Completed
Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study[NCT02787525]1,000 participants (Actual)Observational2016-07-31Completed
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710]10,179 participants (Actual)Observational2010-06-30Completed
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: A Multicenter, Prospective Registry[NCT00596570]996 participants (Actual)Observational2007-01-31Completed
Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709]Phase 47 participants (Actual)Interventional2016-04-30Completed
The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236]150 participants (Actual)Interventional2016-07-31Completed
Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815]Phase 4296 participants (Actual)Interventional2014-09-19Completed
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention[NCT01830543]Phase 32,124 participants (Actual)Interventional2013-05-10Completed
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254]Phase 4420 participants (Anticipated)Interventional2013-08-31Recruiting
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890]Phase 4510 participants (Anticipated)Interventional2018-09-01Recruiting
Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319]1,000 participants (Anticipated)Observational2009-03-31Active, not recruiting
Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633]Phase 4614 participants (Actual)Interventional2008-09-30Active, not recruiting
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]Phase 37,554 participants (Actual)Interventional2003-06-30Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574]84 participants (Actual)Observational2019-02-26Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838]1,200 participants (Anticipated)Observational2023-08-09Recruiting
[NCT02937025]Phase 1/Phase 2154 participants (Anticipated)Interventional2017-01-31Not yet recruiting
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545]Phase 2/Phase 3800 participants (Actual)Interventional2005-02-28Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944]Phase 4400 participants (Anticipated)Interventional2015-10-13Completed
Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794]300 participants (Actual)Observational [Patient Registry]2018-03-14Completed
Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871]300 participants (Anticipated)Observational2020-07-20Not yet recruiting
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178]Phase 36,706 participants (Actual)Interventional2003-07-31Terminated
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948]1,080 participants (Anticipated)Observational [Patient Registry]2018-02-09Active, not recruiting
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414]12 participants Observational2000-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Time to Adjudicated All Cause Death

Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg55
Dabigatran Etexilate 150mg30
Warfarin48
Warfarin (Excluding Elder Patients Outside USA)35

Time to Adjudicated CV

"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg37
Dabigatran Etexilate 150mg21
Warfarin31
Warfarin (Excluding Elder Patients Outside USA)24

Time to Adjudicated Non-CV

"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg14
Dabigatran Etexilate 150mg4
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to Adjudicated Undetermined Cause of Death

"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg4
Dabigatran Etexilate 150mg5
Warfarin4
Warfarin (Excluding Elder Patients Outside USA)3

Time to Composite Endpoint of Death + MI + Stroke

Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg107
Dabigatran Etexilate 150mg60
Warfarin80
Warfarin (Excluding Elder Patients Outside USA)57

Time to Composite Endpoint of Death or First Thrombotic Event

Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg108
Dabigatran Etexilate 150mg60
Warfarin83
Warfarin (Excluding Elder Patients Outside USA60
All Dabigatran Etexilate168

Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg149
Dabigatran Etexilate 150mg90
Warfarin131
Warfarin (Excluding Elder Patients Outside USA)98
All Dabigatran Etexilate239

Time to First Adjudicated ISTH MBE or CRNMBE

"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg151
Dabigatran Etexilate 150mg154
Warfarin264
Warfarin (Excluding Elder Patients Outside USA)196

Time to First Adjudicated MI

Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg44
Dabigatran Etexilate 150mg26
Warfarin29
Warfarin (Excluding Elder Patients Outside USA)22

Time to First Adjudicated SE

"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg3
Dabigatran Etexilate 150mg1
Warfarin3
Warfarin (Excluding Elder Patients Outside USA)3

Time to First Adjudicated ST

Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg15
Dabigatran Etexilate 150mg7
Warfarin8
Warfarin (Excluding Elder Patients Outside USA)7

Time to First Adjudicated Stroke

"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg17
Dabigatran Etexilate 150mg9
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to First Adjudicated Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg76
Dabigatran Etexilate 150mg51
Warfarin69
Warfarin (Excluding Elder Patients Outside USA)52

Percentage of Participants With Clinically Significant Bleeding

Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of >=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to <15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event. (NCT01830543)
Timeframe: Up to Month 12

Interventionpercentage of participants (Number)
Rivaroxaban 15 mg15.7
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)16.6
Vitamin K Antagonist (VKA)24.0

Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)

A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 696, 706, 697)End of DAPT-1 Month (n= 0, 108, 113)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 350, 341)
Rivaroxaban 15 mg13.4NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)14.416.712.914.9
Vitamin K Antagonist (VKA)19.918.62318.2

Percentage of Participants With Cardiovascular Death

The percentage of participants with the first occurrence of cardiovascular death were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 694, 704, 695)End of DAPT-1 Month (n= 0, 108, 112)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 348, 340)
Rivaroxaban 15 mg2.2NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)21.92.41.7
Vitamin K Antagonist (VKA)1.61.81.61.5

Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)

Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 694, 704, 695)End of DAPT-1 Month (n= 0, 108, 112)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 348, 340)
Rivaroxaban 15 mg5.9NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)5.15.66.54
Vitamin K Antagonist (VKA)5.24.53.76.5

Percentage of Participants With Myocardial Infarction

The percentage of participants with the first occurrence of Myocardial Infarction were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 694, 704, 695)End of DAPT-1 Month (n= 0, 108, 112)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 348, 340)
Rivaroxaban 15 mg2.7NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)2.42.82.82
Vitamin K Antagonist (VKA)30.92.54.1

Percentage of Participants With Stent Thrombosis

The percentage of participants with the first occurrence of stent thrombosis were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 694, 704, 695)End of DAPT-1 Month (n= 0, 108, 112)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 348, 340)
Rivaroxaban 15 mg0.7NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)0.91.91.60
Vitamin K Antagonist (VKA)0.60.90.40.6

Percentage of Participants With Stroke

The percentage of participants with the first occurrence of Stroke were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 694, 704, 695)End of DAPT-1 Month (n= 0, 108, 112)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 348, 340)
Rivaroxaban 15 mg1.2NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)1.41.92.40.6
Vitamin K Antagonist (VKA)12.701.2

Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of >= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of >=15 percent). (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 696, 706, 697)End of DAPT-1 Month (n= 0, 108,113)End of DAPT-6 Month (n= 0, 248,243)End of DAPT-12 Month (n= 0, 350,341)
Rivaroxaban 15 mg2.0NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)1.70.92.81.1
Vitamin K Antagonist (VKA)2.94.43.71.8

Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding

TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to <5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to <15 percent). (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12

,,
Interventionpercentage of participants (Number)
Up to Month 12 (n= 696, 706, 697)End of DAPT-1 Month (n= 0, 108, 113)End of DAPT-6 Month (n= 0, 248, 243)End of DAPT-12 Month (n= 0, 350, 341)
Rivaroxaban 15 mg1.0NANANA
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)1.00.90.41.4
Vitamin K Antagonist (VKA)1.91.82.51.5

Adjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA251
Placebo + ASA162

Death From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA825
Placebo + ASA841

Occurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA296
Placebo + ASA408

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Non-CNS systemic embolism- Vascular death
Clopidogrel + ASA8328428550413
Placebo + ASA92410539148380

Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death

A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years

Interventionevents per 100 pt yrs (Number)
Implantable Device2.2
Warfarin Control3.7

Procedure Success

Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure

Interventionpercentage of implant attempts (Number)
WATCHMAN90.9

The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events

Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years

InterventionEvents per 100 pt-yrs (Number)
Implantable Device3.5
Warfarin Control3.2

Reviews

47 reviews available for ticlopidine and Atrial Fibrillation

ArticleYear
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2017
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Zhonghua xin xue guan bing za zhi, 2017, Jun-24, Volume: 45, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He

2017
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Clinical research in cardiology : official journal of the German Cardiac Society, 2018, Volume: 107, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule

2018
Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2013, Volume: 13, Issue:5

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2013
Pharmacokinetic considerations for antithrombotic therapies in stroke.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor

2013
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
    The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru

2014
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
    The American journal of medicine, 2014, Volume: 127, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibri

2014
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Clinical therapeutics, 2014, Sep-01, Volume: 36, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2014
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.
    Journal of the American College of Cardiology, 2014, Sep-23, Volume: 64, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Percutaneous Coronary Interventio

2014
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination;

2015
Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.
    Polskie Archiwum Medycyny Wewnetrznej, 2015, Volume: 125, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; He

2015
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug

2015
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
    International journal of cardiology, 2015, Oct-01, Volume: 196

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinati

2015
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
    Stroke, 2009, Volume: 40, Issue:12

    Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases;

2009
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
    Vascular health and risk management, 2010, Mar-03, Volume: 6

    Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio

2010
[New aspects on "triple therapy" after coronary stent implantation].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:41

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation;

2010
Triple therapy in hospitalized patients: facts and controversies.
    Journal of hospital medicine, 2011, Volume: 6, Issue:9

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2011
Clopidogrel hydrogen sulphate for atrial fibrillation.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel

2011
New insights in antiplatelet therapy for patients with ischemic stroke.
    The neurologist, 2011, Volume: 17, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I

2011
[Clopidogrel and stroke].
    Revista de neurologia, 2011, Nov-01, Volume: 53, Issue:9

    Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm

2011
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel;

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr

2012
Impact of antiplatelet therapy in heart disease.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2012
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr

2012
Challenges in atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C

2012
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    American heart journal, 2003, Volume: 145, Issue:3

    Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole;

2003
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
    Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:9 Suppl

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate

2003
Trials of newer approaches to anticoagulation in atrial fibrillation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2004, Volume: 10 Suppl 1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Interna

2004
Atrial fibrillation: should we target platelets or the coagulation pathway?
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment;

2003
Preparing for the post-warfarin generation of antithrombotics.
    The American journal of managed care, 2004, Volume: 10, Issue:10 Suppl

    Topics: Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clopidogrel; Fibrinolytic Agents; Fon

2004
New possibilities in anticoagulant management of atrial fibrillation.
    Reviews in cardiovascular medicine, 2004, Volume: 5 Suppl 5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Oligosa

2004
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur

2005
[Preventing cerebrovascular accidents during atrial fibrillation].
    Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18

    Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi

2006
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
    American heart journal, 2008, Volume: 155, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Tri

2008
Antiplatelet therapy for stroke prevention.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:4

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel

2007
Medical treatment for stroke prevention.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Antithrombotic therapies for stroke prevention.
    Current opinion in neurology, 1994, Volume: 7, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti

1994
[Antithrombotic agents and prevention of cerebrovascular accidents].
    Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clopidogrel; Echocardiography; Humans; Intr

1996
[A case of mobile left atrial thrombus without mitral valve disease].
    Kyobu geka. The Japanese journal of thoracic surgery, 1997, Volume: 50, Issue:9

    Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Heart Atria; He

1997
Antiplatelet agents and stroke prevention.
    Seminars in neurology, 1998, Volume: 18, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipy

1998
Stroke: part I. A clinical update on prevention.
    American family physician, 1999, May-01, Volume: 59, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic;

1999
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:7

    Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Cholestasis; Chro

2000
[Prevention of recurrence in cerebral infarction].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2002, Mar-20, Volume: 91 Suppl

    Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebral Infarction; Drug Therapy, C

2002

Trials

29 trials available for ticlopidine and Atrial Fibrillation

ArticleYear
Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial.
    Contemporary clinical trials, 2017, Volume: 60

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Endoscopy, Digestive System; G

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema

2014
One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry.
    Clinical cardiology, 2014, Volume: 37, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Vessels; Female; Fibrinolytic Agents; Humans; Ma

2014
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
    Contemporary clinical trials, 2015, Volume: 40

    Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combina

2015
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid

2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention
    American heart journal, 2015, Volume: 169, Issue:4

    Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Re

2015
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug

2015
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
    BioMed research international, 2015, Volume: 2015

    Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogr

2015
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Journal of cardiology, 2017, Volume: 69, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin

2017
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D

2016
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
    Circulation, 2008, Nov-11, Volume: 118, Issue:20

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brazil;

2008
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
[Clopidogrel in the treatment of atrial fibrillation: benefit from addition to aspirin. The results of ACTIVE A trial].
    Kardiologiia, 2009, Volume: 49, Issue:5

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Follow-Up S

2009
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt

2010
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cyto

2010
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial

2011
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial.
    Coronary artery disease, 2012, Volume: 23, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Cor

2012
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascula
    Circulation. Cardiovascular genetics, 2012, Apr-01, Volume: 5, Issue:2

    Topics: Adult; Aged; Angina, Unstable; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Female; Hum

2012
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
    Journal of the American College of Cardiology, 2002, Aug-07, Volume: 40, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clopidogrel;

2002
Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation.
    Thrombosis and haemostasis, 2003, Volume: 89, Issue:5

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Interactions; Drug

2003
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study.
    American heart journal, 2004, Volume: 148, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Bleeding Time; Clopidogrel; Drug Therapy, Combin

2004
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
    American heart journal, 2006, Volume: 151, Issue:6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel;

2006
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Journal of the American College of Cardiology, 2007, Nov-27, Volume: 50, Issue:22

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co

2007
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Ele

2008
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny

2008

Other Studies

128 other studies available for ticlopidine and Atrial Fibrillation

ArticleYear
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation.
    Pharmacology, 2022, Volume: 107, Issue:3-4

    Topics: Acute Coronary Syndrome; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Cytochrome P-450

2022
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    JACC. Cardiovascular interventions, 2017, 06-12, Volume: 10, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A

2017
WATCHMAN device-related thrombus successfully treated with apixaban: A case report.
    Medicine, 2017, Volume: 96, Issue:47

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibit

2017
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
    BMJ case reports, 2018, May-30, Volume: 2018

    Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diag

2018
Amplatzer left atrial appendage occlusion: single center 10-year experience.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Aug-01, Volume: 82, Issue:2

    Topics: Aged; Aged, 80 and over; Anesthesia, Local; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac

2013
PCI patients taking oral anticoagulants may not need aspirin.
    BMJ (Clinical research ed.), 2013, Feb-20, Volume: 346

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Clopidogrel; Drug Therapy, Combination

2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
    MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3

    Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel;

2013
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Journal of the American College of Cardiology, 2013, Sep-10, Volume: 62, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2013
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru

2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
    International journal of clinical practice, 2013, Volume: 67, Issue:8

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis

2013
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
    Heart and vessels, 2014, Volume: 29, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co

2014
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therap

2014
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
    Cardiovascular intervention and therapeutics, 2014, Volume: 29, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera

2014
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Circulation, 2014, Apr-15, Volume: 129, Issue:15

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2014
Lower gastrointestinal bleeding associated with diclofenac topical patch in a patient with colonic mass and on antiplatelet therapy for atrial fibrillation.
    American journal of physical medicine & rehabilitation, 2014, Volume: 93, Issue:11

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Clopidogrel; Colonic Neoplasms;

2014
Intracranial hemorrhage during dual antiplatelet therapy after percutaneous left atrial appendage closure.
    Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 38, Issue:1

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
    The Medical journal of Australia, 2014, Nov-17, Volume: 201, Issue:10

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti

2014
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr

2015
Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
    Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K

2015
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
    Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K

2015
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
    MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2

    Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap

2015
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
    Neurological research, 2015, Volume: 37, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti

2015
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
    Chest, 2015, Volume: 148, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido

2015
Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience.
    Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:2

    Topics: Acenocoumarol; Aged; Aged, 80 and over; Aortic Valve Stenosis; Atrial Fibrillation; Clopidogrel; Fem

2015
Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage.
    JAMA ophthalmology, 2015, Volume: 133, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibitors; Hum

2015
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Harefuah, 2015, Volume: 154, Issue:5

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors

2015
Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal.
    International journal of cardiology, 2015, Dec-15, Volume: 201

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Coronary Angiogr

2015
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel;

2015
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance.
    International journal of cardiology, 2016, Jan-01, Volume: 202

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clopidogrel; D

2016
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders.
    International journal of cardiology, 2016, Feb-01, Volume: 204

    Topics: Aged; Aged, 80 and over; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Female; Heart Diseases;

2016
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    The American journal of medicine, 2016, Volume: 129, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity;

2016
Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Humans;

2016
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Surgical Procedures; Clopido

2016
Another side effect of ticagrelor: Atrial fibrillation.
    International journal of cardiology, 2016, Jun-01, Volume: 212

    Topics: Adenosine; Aged; Angina, Unstable; Atrial Fibrillation; Clopidogrel; Humans; Male; Ticagrelor; Ticlo

2016
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Feb-01, Volume: 89, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
    Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:8

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modal

2016
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
    World neurosurgery, 2016, Volume: 95

    Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra

2016
The Triple Challenge of Triple Therapy.
    JACC. Cardiovascular interventions, 2016, 08-22, Volume: 9, Issue:16

    Topics: Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Platelet Aggregation Inhibitors; Tic

2016
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    American heart journal, 2016, Volume: 179

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran

2016
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2017
Atrial Fibrillation and PCI - Do We Still Need Aspirin?
    The New England journal of medicine, 2016, 12-22, Volume: 375, Issue:25

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

2016
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
    Archives of cardiovascular diseases, 2017, Volume: 110, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl

2017
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
    European heart journal, 2017, Mar-21, Volume: 38, Issue:12

    Topics: Adenosine; Antithrombins; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Endocardium; Heart Atr

2017
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Chest, 2008, Volume: 134, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As

2008
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Medizinische Klinik (Munich, Germany : 1983), 2008, Sep-15, Volume: 103, Issue:9

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir

2008
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I

2009
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
    The Lancet. Neurology, 2009, Volume: 8, Issue:6

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra

2009
[Clopidogrel in the treatment of atrial fibrillation: comparison with warfarin. The results of ACTIVE W trial].
    Kardiologiia, 2009, Volume: 49, Issue:5

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dose-Response Relationship, Drug; Follow-Up

2009
Prevention of stroke in patients with atrial fibrillation.
    The Medical letter on drugs and therapeutics, 2009, Jun-01, Volume: 51, Issue:1313

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans;

2009
[Cardiology 2009].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:25-26

    Topics: Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Cardiology; Cardiovascular Diseases; Clopidogrel

2009
[ASS plus clopidogrel in contraindication for marcumar].
    MMW Fortschritte der Medizin, 2009, Apr-16, Volume: 151, Issue:16

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat

2009
Who is ineligible for warfarin in atrial fibrillation?
    Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans;

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet A

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Pla

2009
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri

2009
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic;

2009
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica

2009
By the way, doctor. I am currently on Coumadin because I had atrial fibrillation after my bypass, Plavix because of my stent, and a baby aspirin. Why do I need to take three blood thinners?
    Harvard health letter, 2009, Volume: 34, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiopulmonary Bypass; Clopidogrel; Humans; Platelet

2009
Aspirin gets a backup against atrial fibrillation.
    Harvard heart letter : from Harvard Medical School, 2009, Volume: 19, Issue:11

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I

2009
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini

2009
[Abdominal tumor after persistent coughing and uncontrolled anticoagulation].
    Praxis, 2010, Jan-06, Volume: 99, Issue:1

    Topics: Abdomen, Acute; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coloni

2010
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor

2010
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
    Der Nervenarzt, 2010, Volume: 81, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel;

2010
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis

2010
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
    MMW Fortschritte der Medizin, 2010, Mar-25, Volume: 152, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar

2010
Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
    The Medical journal of Australia, 2010, May-03, Volume: 192, Issue:9

    Topics: Algorithms; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Vessels; Drug Therapy, Combination;

2010
[Perioperative use of antithrombotic agents: recommendations of the American College of Chest Physicians (ACCP) and the French Superior Health Authority (HAS)].
    Journal des maladies vasculaires, 2010, Volume: 35, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Clopidogrel; Fibrinolytic Agents;

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Ischaemic stroke--prevention is better than cure.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo

2010
CYP2C19 genotype and outcomes of clopidogrel treatment.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome

2011
Atrial fibrillation, is warfarin the only option for stroke prevention?
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cl

2011
Atrial fibrillation, is warfarin the only option for stroke prevention?
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
Dual antiplatelet therapy and the risk of bleeding.
    Archives of internal medicine, 2011, Apr-25, Volume: 171, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag

2011
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
    International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
Atrial fibrillation treatment update.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2011, Volume: 64, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Heart Rate; Humans; Platelet Aggregation Inhibitors; Prac

2011
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
    Stroke, 2011, Volume: 42, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Femal

2011
Thrombus formation on a left atrial appendage closure device.
    Circulation, 2011, Oct-04, Volume: 124, Issue:14

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design;

2011
Clinical update on nursing home medicine: 2011.
    Journal of the American Medical Directors Association, 2011, Volume: 12, Issue:9

    Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir

2011
Selecting the optimal stroke prevention therapy in atrial fibrillation.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib

2011
Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease.
    JAMA, 2011, Dec-07, Volume: 306, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interaction

2011
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    The American journal of cardiology, 2012, Apr-01, Volume: 109, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Cohort St

2012
Warfarin use in nursing home residents: results from the 2004 national nursing home survey.
    The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cross-Sectional

2012
[Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation T

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2012, Jul-01, Volume: 110, Issue:1

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla

2012
Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
    Circulation. Cardiovascular genetics, 2012, Apr-01, Volume: 5, Issue:2

    Topics: Angina, Unstable; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Female; Humans; Male; Po

2012
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A

2012
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat

2012
Clopidogrel in atrial fibrillation: is there any justification now in the era of new anticoagulants?
    The American journal of cardiology, 2012, Jul-01, Volume: 110, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Practice Guideli

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh

2012
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo

2012
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Circulation, 2012, Sep-04, Volume: 126, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi

2012
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
    American heart journal, 2012, Volume: 164, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor

2012
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2012, Volume: 40, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2012
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combinat

2013
Stroke prevention in patients with atrial fibrillation.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2003, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; F

2003
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp

2003
[Anticoagulation and antiaggregation in cardiac patients].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo

2003
Spontaneous pharyngeal haemorrhage in the anticoagulated patient.
    Irish medical journal, 2003, Volume: 96, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Male; Pharyngeal Disease

2003
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 60, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia

2003
Proximal deep venous thrombosis occurring after sudden clopidogrel suspension.
    European journal of clinical pharmacology, 2004, Volume: 60, Issue:1

    Topics: Aged; Atrial Fibrillation; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Prognosis; Su

2004
Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR.
    American heart journal, 2005, Volume: 149, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clopidogrel; Drug

2005
Clopidogrel as antithrombotic therapy in atrial fibrillation.
    Chest, 2005, Volume: 128, Issue:1

    Topics: Atrial Fibrillation; Atrial Flutter; Clopidogrel; Electric Countershock; Evidence-Based Medicine; Fi

2005
[Prophylaxis of stroke].
    Praxis, 2005, Jul-27, Volume: 94, Issue:30-31

    Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi

2005
[Even in 60-year-old atrial fibrillation is not uncommon. Advances in long-term treatment].
    MMW Fortschritte der Medizin, 2006, Apr-13, Volume: 148, Issue:15

    Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillat

2006
Good old warfarin for stroke prevention in atrial fibrillation.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pla

2006
Saddle embolism after corrective femoral osteotomy: a case report.
    Journal of orthopaedic surgery (Hong Kong), 2006, Volume: 14, Issue:2

    Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em

2006
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
    Chest, 2006, Volume: 130, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2006
Prevention of vascular events in atrial fibrillation.
    Lancet (London, England), 2007, Jan-13, Volume: 369, Issue:9556

    Topics: Accidental Falls; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggreg

2007
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    Pharmacotherapy, 2007, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2007
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Der Internist, 2007, Volume: 48, Issue:8

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny

2007
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
    Internal and emergency medicine, 2007, Volume: 2, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly

2007
Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2007, Volume: 13, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Follow-Up Studies; Hemophilia A; Heparin; HIV Infe

2007
Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
    The American journal of medicine, 2007, Volume: 120, Issue:11

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Practice Guidelines as Topic

2007
Guidelines for medical treatment for stroke prevention. American College of Physicians.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
    Clinical therapeutics, 1998, Volume: 20 Suppl B

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa

1998
[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy].
    Journal of cardiology, 1998, Volume: 31, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Female; Heart Diseases; Humans; Male; Mi

1998
Sex differences and similarities in the management and outcome of stroke patients.
    Stroke, 2000, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity;

2000
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole

2000
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
    Stroke, 2001, Dec-01, Volume: 32, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2001
Platelet aggregation behaviour in patients treated with ticlopidine.
    Drugs under experimental and clinical research, 1987, Volume: 13, Issue:1

    Topics: Adult; Aged; Aspirin; Atrial Fibrillation; Bleeding Time; Dipyridamole; Female; Humans; Male; Middle

1987